Skip to the answer

Levetiracetam Uses, Dosage, Side Effects and Interactions

Brand names
Elepsia XR

Elepsia XR came 19 years after Keppra (December 2018) as an extended-release tablet. An FDA-approved generic with the same active ingredient is listed.

First generic of Elepsia XR: our estimate, October 2027

Keppra

Keppra was the first levetiracetam product the FDA approved, in November 1999. An FDA-approved generic with the same active ingredient is listed.

Keppra XR

Keppra XR came 8 years after Keppra (September 2008). An FDA-approved generic with the same active ingredient is listed.

Spritam

Spritam came 15 years after Keppra (July 2015) as a tablet. The FDA rates no generic as a substitute for it.

Roweepra

Roweepra is a brand of levetiracetam that comes as a tablet. An FDA-approved generic with the same active ingredient is listed.

Levetiracetam is an antiseizure medicine used for partial-onset seizures, and as add-on treatment for myoclonic seizures in juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures in idiopathic generalized epilepsy, in oral and intravenous forms.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 19, 2026 Where our facts come from

Quick links

Ask Anything About LevetiracetamType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Levetiracetam in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Levetiracetam (Keppra) is one of the most widely prescribed antiseizure medicines, often a first choice for partial-onset seizures (those that start in one area of the brain) and an add-on for some generalized seizures; it seems to work by binding SV2A, a nerve-cell protein that helps control chemical signaling, and it has been on the U.S. market since about 1999, with FDA-approved generics listed. Most people tolerate it well, and sleepiness, tiredness and dizziness are what they usually notice, often easing over the first few weeks. Watch for irritability, aggression (more common in children), depression or suicidal thoughts, and report any new mood change promptly.

Key Takeaways From the HelloPharmacist Team

  • Expect to take it twice a day (extended-release once a day, swallowed whole), with the dose usually raised every 2 weeks.
  • Never stop it suddenly or let a refill lapse, because stopping abruptly can bring on more seizures.
  • Hold off on driving or using machinery until you know how much sleepiness or unsteadiness it causes you.
  • Call your doctor at the first sign of a rash, and get emergency care for swelling of the lips, tongue or throat.

How we write and review this content: our editorial policy

Levetiracetam by the Numbers

Strengths
13
across 4 forms
Makers and packagers
84
Earliest FDA record
1999
Rank by Medicaid prescriptions
#73 of 1,682 drugs
More prescriptions than 95% of the 1,682 drugs we measure
3.06 million prescriptions, Q1–Q4 2025
Other forms and routes

Patient Information Guide for Levetiracetam

What It’s Used For

Levetiracetam is an antiseizure medicine with several approved uses, depending on the product.

  • Partial-onset seizures: Keppra, Roweepra and other immediate-release tablets, oral solution and injection are labeled from 1 month of age. Spritam is labeled for ages 4 and older weighing over 20 kg.
  • Partial-onset seizures: Keppra XR and Levetiracetam ER are labeled for ages 12 and older. Elepsia XR is labeled as add-on therapy for ages 12 and older.
  • Add-on therapy for myoclonic seizures in juvenile myoclonic epilepsy, ages 12 and older (immediate-release oral products, Spritam and injection).
  • Add-on therapy for primary generalized tonic-clonic seizures in idiopathic generalized epilepsy, ages 6 and older (immediate-release oral products, Spritam and injection).
  • Injection: only when oral use is temporarily not feasible. Levetiracetam in Sodium Chloride injection is labeled for adults 16 and older.

How It Works

The exact way levetiracetam prevents seizures is unknown. It binds to a protein called SV2A on nerve cells, which is thought to help control the release of chemical messengers between nerves.

In animal studies, how strongly similar compounds bound to SV2A matched their antiseizure strength. This suggests the binding may play a role.

Drug Class

What It Does in the Body

  • Decreased Central Nervous System Disorganized Electrical Activity
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)

None listed for Levetiracetam in the FDA’s index.

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)

None listed for Levetiracetam in the FDA’s index.

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)
  • Decreased Central Nervous System Disorganized Electrical Activity

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Levetiracetam in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Other antiepileptics

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Levetiracetam comes as tablets, oral solution, extended-release tablets and an injection. Always follow your prescriber's directions and the product label.

  • Immediate-release tablets and oral solution are usually taken by mouth twice daily.
  • Extended-release tablets are taken once daily and swallowed whole.
  • The injection is given into a vein over about 15 minutes by a healthcare professional.
  • Doses usually start low and increase gradually. Kidney function can change the dose.
  • Don't stop suddenly. Ask your pharmacist or doctor what to do about a missed dose.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Levetiracetam Tablets and Oral Solution

Partial-onset seizures
Adults 16 years and older Starting dose 500 mg twice a day Usual dose 1500 mg twice a day Highest dose 3000 mg a day
  • Increase by 500 mg twice daily every 2 weeks to a recommended dose of 1500 mg twice daily
Children 1 month to less than 6 months old Starting dose 7 mg/kg twice a day Usual dose 21 mg/kg twice a day
  • Increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily

Good to know

Use oral solution for weight 20 kg or less

Children 6 months to less than 4 years old Starting dose 10 mg/kg twice a day Usual dose 25 mg/kg twice a day
  • Increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily

Good to know

Use oral solution for weight 20 kg or less

Children 4 to less than 16 years old Starting dose 10 mg/kg twice a day Usual dose 30 mg/kg twice a day
  • Increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily

Good to know

Use oral solution for weight 20 kg or less

Myoclonic seizures in juvenile myoclonic epilepsy
For adults and children 12 years and older
Starting dose 500 mg twice a day Usual dose 1500 mg twice a day
  • Increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily
Primary generalized tonic-clonic seizures
Adults 16 years and older Starting dose 500 mg twice a day Usual dose 1500 mg twice a day
  • 500 mg twice daily, increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily
Children 6 to less than 16 years old Starting dose 10 mg/kg twice a day Usual dose 30 mg/kg twice a day
  • 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily
Kidney problems, normal (CLcr > 80 mL/min/1.73m2)
For adults
Dose 500 to 1,500 mg every 12 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

Kidney problems, mild (CLcr 50 – 80 mL/min/1.73m2)
For adults
Dose 500 to 1,000 mg every 12 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

Kidney problems, moderate (CLcr 30 – 50 mL/min/1.73m2)
For adults
Dose 250 to 750 mg every 12 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

Kidney problems, severe (CLcr < 30 mL/min/1.73m2)
For adults
Dose 250 to 500 mg every 12 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

Adults with kidney failure (ESRD) using
For adults on dialysis
Usual dose 250 to 500 mg

Step by step

  1. 500 to 1,000 mg every 24 hours
  2. Following dialysis, a 250 to 500 mg supplemental dose is recommended

ESRD means end-stage renal disease (kidney failure).

See the Full Dosing Instructions on DailyMed →

Levetiracetam Extended-Release Tablets

Seizures (extended-release tablets)
For adults and teens 12 years and older weighing 50 kg or more
Starting dose 1,000 mg once a day Highest dose 3,000 mg once a day

Step by step

  1. Initiate 1,000 mg once daily
  2. Increase by 1,000 mg every 2 weeks
Extended-release tablets, with normal kidney function (CLcr > 80)
For adults
Dose 1,000 to 3,000 mg every 24 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

Extended-release tablets, with mild kidney problems (CLcr 50 - 80)
For adults
Dose 1,000 to 2,000 mg every 24 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

Extended-release tablets, with moderate kidney problems (CLcr 30 - 50)
For adults
Dose 500 to 1,500 mg every 24 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

Extended-release tablets, with severe kidney problems (CLcr < 30)
For adults
Dose 500 to 1,000 mg every 24 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

See the Full Dosing Instructions on DailyMed →

Spritam

Partial-onset seizures
For adults and children weighing over 40 kg
Starting dose 500 mg twice a day Highest dose 1,500 mg twice a day

Step by step

  1. 500 mg twice daily (1,000 mg daily)
  2. Increase by 500 mg twice daily every 2 weeks
Myoclonic and primary generalized tonic-clonic seizures
For adults and children weighing over 40 kg
Starting dose 500 mg twice a day Usual dose 1,500 mg twice a day

Step by step

  1. 500 mg twice daily (1,000 mg daily)
  2. Increase by 500 mg twice daily every 2 weeks to recommended 1,500 mg twice daily (3,000 mg daily)

These are the doses for children. For adults, see “Partial-onset seizures.”

Seizures (Spritam)
For children weighing 20 kg to 40 kg
Starting dose 250 mg twice a day Highest dose 750 mg twice a day

Step by step

  1. 250 mg twice daily (500 mg daily)
  2. Increase by 250 mg twice daily every 2 weeks
Spritam, with normal kidney function (CLcr >80)
For adults
Dose 500 to 1,500 mg every 12 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

Spritam, with mild kidney problems (CLcr 50-80)
For adults
Dose 500 to 1,000 mg every 12 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

Spritam, with moderate kidney problems (CLcr 30-50)
For adults
Dose 250 to 750 mg every 12 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

Spritam, with severe kidney problems (CLcr <30)
For adults
Dose 250 to 500 mg every 12 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

Spritam, adults with kidney failure (ESRD) using
For adults on dialysis
Usual dose 250 to 500 mg

Step by step

  1. 500 to 1,000 mg every 24 hours
  2. Following dialysis, a 250 to 500 mg supplemental dose is recommended

ESRD means end-stage renal disease (kidney failure).

See the Full Dosing Instructions on DailyMed →

Levetiracetam Injection

Partial-onset seizures
Injection, partial-onset seizures Starting dose 500 mg twice a day Highest dose 1,500 mg twice a day
  • Increase by 500 mg twice daily every 2 weeks

Good to know

Given as a 15-minute infusion; not diluted

Adults 16 years and older · Keppra 500 mg Starting dose 500 mg twice a day Usual dose 1,500 mg twice a day Highest dose 3,000 mg a day
  • Increase by 500 mg twice daily every 2 weeks to a recommended dose of 1,500 mg twice daily

Keppra is a brand name for this medicine. See Keppra’s full dosing instructions on DailyMed →

Children 1 month to less than 6 months old · Keppra 7 mg/kg Starting dose 7 mg/kg twice a day Usual dose 21 mg/kg twice a day
  • Increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily

Keppra is a brand name for this medicine. See Keppra’s full dosing instructions on DailyMed →

Children 6 months to less than 4 years old · Keppra 10 mg/kg Starting dose 10 mg/kg twice a day Usual dose 25 mg/kg twice a day
  • Increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily

Keppra is a brand name for this medicine. See Keppra’s full dosing instructions on DailyMed →

Children 4 to less than 16 years old · Keppra 10 mg/kg Starting dose 10 mg/kg twice a day Usual dose 30 mg/kg twice a day
  • Increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily

Keppra is a brand name for this medicine. See Keppra’s full dosing instructions on DailyMed →

Myoclonic seizures in juvenile myoclonic epilepsy
Adults Starting dose 500 mg twice a day Usual dose 1,500 mg twice a day
  • Increase by 500 mg twice daily every 2 weeks to the recommended dose of 1,500 mg twice daily
Adults and children 12 years and older · Keppra 500 mg Starting dose 500 mg twice a day Usual dose 1,500 mg twice a day
  • Increase by 500 mg twice daily every 2 weeks to recommended dose of 1,500 mg twice daily

Keppra is a brand name for this medicine. See Keppra’s full dosing instructions on DailyMed →

Primary generalized tonic-clonic seizures
Adults Starting dose 500 mg twice a day Usual dose 1,500 mg twice a day
  • Increase by 500 mg twice daily every 2 weeks to the recommended dose of 1,500 mg twice daily
Adults 16 years and older · Keppra 500 mg Starting dose 500 mg twice a day Usual dose 1,500 mg twice a day
  • Increase by 500 mg twice daily every 2 weeks to recommended dose of 1,500 mg twice daily

Keppra is a brand name for this medicine. See Keppra’s full dosing instructions on DailyMed →

Children 6 to less than 16 years old · Keppra 10 mg/kg Starting dose 10 mg/kg twice a day Usual dose 30 mg/kg twice a day
  • Increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily

Keppra is a brand name for this medicine. See Keppra’s full dosing instructions on DailyMed →

Injection, with normal kidney function (CLcr > 80)
For adults
Dose 500 to 1,500 mg every 12 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

Injection, with mild kidney problems (CLcr 50 – 80)
For adults
Dose 500 to 1,000 mg every 12 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

Injection, with moderate kidney problems (CLcr 30 – 50)
For adults
Dose 250 to 750 mg every 12 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

Injection, with severe kidney problems (CLcr < 30)
For adults
Dose 250 to 500 mg every 12 hours

CrCl means creatinine clearance, a measure of how well the kidneys work.

See the Full Dosing Instructions on DailyMed →

Side Effects

Many side effects show up early, often in the first month.

Common side effects

  • Sleepiness (somnolence)
  • Weakness or tiredness (asthenia, fatigue)
  • Dizziness
  • Infections
  • Headache
  • In children: aggression, irritability, decreased appetite, nasal congestion
  • Coordination problems

When to get medical help

  • Call your doctor right away for new or worsening depression, suicidal thoughts, or unusual mood or behavior changes.
  • Get help for hallucinations, paranoia, confusion, or severe agitation or aggression.
  • Seek emergency care for swelling of the face, lips, tongue or throat, hives, or trouble breathing (anaphylaxis or angioedema).
  • Stop and call your doctor at the first sign of a rash, which can signal a serious skin reaction such as Stevens-Johnson syndrome.
  • Get evaluated right away for fever, swollen glands, rash or facial swelling, which may signal DRESS (a serious multiorgan allergic reaction).
  • Tell your doctor about significant weakness, fever, or repeated infections, since blood counts can drop.
  • Report unsteadiness, trouble walking, or poor coordination.

Warnings and Precautions

  • Suicidal thoughts and behavior: antiepileptic drugs raise this risk slightly. Watch for new or worsening depression or mood changes.
  • Behavior and psychotic symptoms: aggression, irritability, paranoia or hallucinations can occur, especially in children.
  • Sleepiness and coordination problems: avoid driving until you know how it affects you.
  • Allergic and skin reactions: anaphylaxis, angioedema, Stevens-Johnson syndrome and DRESS have been reported. Stop and get help at the first sign of rash or swelling.
  • Blood count changes: report significant weakness, fever or repeated infections.
  • Stopping suddenly: can increase seizures. It is usually withdrawn gradually.

Interactions

Levetiracetam has few drug interactions.

  • Other antiepileptic drugs such as phenytoin, valproate, carbamazepine and lamotrigine did not change levetiracetam levels, nor did it change theirs.
  • Birth control pills: no effect on their action was seen.
  • Warfarin and digoxin: no effect was seen.
  • Probenecid: raised levels of an inactive breakdown product only.

Interactions Listed in the FDA-Approved Label

From the Levetiracetam prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • What happensLevetiracetam did not affect phenytoin pharmacokinetics, and phenytoin did not affect levetiracetam.
  • Valproate
    What happensNeither levetiracetam nor valproate changed the other's pharmacokinetics.
  • Other antiepileptic drugs (carbamazepine, gabapentin, lamotrigine, phenobarbital, primidone, topiramate)
    What happensLevetiracetam does not influence the plasma concentration of other AEDs and they do not influence levetiracetam.
  • Enzyme-inducing antiepileptic drugs in children
    What happensAbout a 22% increase of apparent total body clearance of levetiracetam when co-administered.
    What to doDose adjustment is not recommended.
  • Oral contraceptives
    What happensLevetiracetam did not influence the pharmacokinetics of an oral contraceptive; impairment of contraceptive efficacy is unlikely.
  • What happensLevetiracetam did not influence the pharmacokinetics and pharmacodynamics of digoxin, and digoxin did not influence levetiracetam.
  • What happensLevetiracetam did not influence the pharmacokinetics of R and S warfarin; prothrombin time was not affected.
  • What happensProbenecid did not change levetiracetam pharmacokinetics, but approximately doubled Css max of metabolite ucb L057 and decreased its renal clearance 60%.
Read the label’s full interactions text

Drug Interactions In vitro data on metabolic interactions indicate that levetiracetam is unlikely to produce, or be subject to, pharmacokinetic interactions. Levetiracetam and its major metabolite, at concentrations well above C max levels achieved within the therapeutic dose range, are neither inhibitors of, nor high affinity substrates for, human liver cytochrome P450 isoforms, epoxide hydrolase or UDP-glucuronidation enzymes. In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid. Potential pharmacokinetic interactions of or with levetiracetam were assessed in clinical pharmacokinetic studies (phenytoin, valproate, warfarin, digoxin, oral contraceptive, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients. Phenytoin Levetiracetam (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy. Pharmacokinetics of levetiracetam were also not affected by phenytoin. Valproate Levetiracetam (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers. Valproate 500 mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion. There also was no effect on exposure to and the excretion of the primary metabolite, ucb L057. Other Antiepileptic Drugs Potential drug interactions between levetiracetam and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies. These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.

Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Don't use it if you have had a severe allergic reaction to levetiracetam.
  • Kidney problems: the dose may need adjusting, and extra doses may be needed after dialysis.
  • Pregnancy: blood levels can fall, so your doctor may monitor you closely. A pregnancy registry is available.
  • Breastfeeding: it passes into breast milk, so discuss it with your doctor.
  • Children: age and weight limits vary by product.
  • Older adults: kidney function may be reduced, so dosing needs care.

Overdose

Overdose can cause drowsiness, agitation, aggression, reduced alertness, slowed breathing and coma. There is no specific antidote. Supportive care is given, and hemodialysis can remove a significant amount of the drug. Contact Poison Control or seek emergency help.

Half-Life and How Your Body Processes It

Levetiracetam is absorbed rapidly and almost completely by mouth. The injection and tablets deliver equivalent exposure. Its half-life is about 6 to 8 hours, and longer in older adults and people with kidney problems. About two-thirds of a dose is cleared by the kidneys unchanged. It isn't broken down by liver cytochrome P450 enzymes and binds very little to proteins.

Storage

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) .

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Supplements and Herbs That Interact With Levetiracetam

From the licensed clinical database we use, rolled up per supplement, most serious first.

104 supplements and herbal products have documented interactions with Levetiracetam in the licensed clinical database we use.

Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.

  • 7Major
  • 81Moderate
  • 16Minor

See the other 96

Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Nutrients Levetiracetam May Deplete

Nutrients Levetiracetam has been linked with lower levels of, from the licensed clinical database we use.

Levetiracetam has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur. It means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.

Educational information from a licensed clinical database (Natural Medicines), not medical advice. Do not start or stop medications or supplements without professional guidance.

Levetiracetam: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Levetiracetam — the kind of thing our pharmacy team would talk through with you at the counter.

What is levetiracetam used for?

It treats certain seizure types in epilepsy. It is used for partial-onset seizures. Some products are also used as add-on therapy for myoclonic seizures in juvenile myoclonic epilepsy and generalized tonic-clonic seizures. Which uses apply depends on the product and your age.

Can I stop taking levetiracetam suddenly?

No. Stopping suddenly can increase how often you have seizures and can cause prolonged seizures. Your doctor will usually lower the dose gradually. Talk with them before making any change.

Will levetiracetam make me sleepy, and can I drive?

Sleepiness, tiredness and dizziness are among the most common side effects, mostly in the first month. Don't drive or use machinery until you know how it affects you.

What mood side effects should I watch for?

Levetiracetam can cause irritability, aggression, anxiety or depression. Like other antiepileptic drugs, it can raise the risk of suicidal thoughts. Call your doctor right away about new or worsening mood or behavior changes, hallucinations or paranoia.

Does levetiracetam interact with other medicines or birth control?

It has few interactions. Studies showed no effect on other seizure medicines, warfarin, digoxin, or birth control pills. Still, tell your pharmacist about everything you take.

Is levetiracetam safe in pregnancy?

Long experience hasn't linked it to major birth defects or miscarriage, but animal studies showed harm at similar doses. Blood levels can drop during pregnancy, so your doctor may adjust the dose. Don't stop it on your own, and ask about the pregnancy registry.

Is levetiracetam available over the counter?

No. Levetiracetam is a prescription medicine: every levetiracetam product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was levetiracetam first available?

The earliest FDA record we hold for levetiracetam is from 1999: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when levetiracetam was first used.

Who makes levetiracetam?

84 companies currently list levetiracetam products in the FDA's NDC Directory, including A-S Medication Solutions, Bryant Ranch Prepack, Remedyrepack Inc.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

What is the brand name of levetiracetam?

Levetiracetam is the generic name. Its brand names are Elepsia XR, Keppra, Keppra XR, Spritam and Roweepra. Generic versions are listed under the name levetiracetam.

What is the generic name of Elepsia XR?

The generic name of Elepsia XR is levetiracetam. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

Is there a generic version of levetiracetam?

Yes. FDA-approved generic versions of levetiracetam are listed in the FDA's National Drug Code Directory. A listing does not prove that every pharmacy stocks one, so your pharmacy can tell you which version it carries.

What strengths does levetiracetam come in?

Levetiracetam is listed in the FDA's National Drug Code Directory in these forms and strengths. Tablet (by mouth): 250 mg, 500 mg, 750 mg and 1000 mg. Injection (into a vein): 500 mg/5 mL, 500 mg/100 mL, 1000 mg/100 mL and 1500 mg/100 mL. Extended-release tablet (by mouth): 500 mg, 750 mg, 1000 mg and 1500 mg. Oral solution (by mouth): 100 mg/mL. A listing does not mean every pharmacy stocks every strength.

How much does levetiracetam cost?

What you pay depends on your insurance, your pharmacy and the strength you take. As a benchmark, pharmacies paid a national average of $0.06 to $0.17 per generic tablet across 4 strengths, $8.08 to $10.27 per tablet of brand-name Keppra and Spritam across 3 strengths, $0.18 to $0.25 per generic extended-release tablet across 2 strengths and $9.00 to $13.48 per extended-release tablet of brand-name Keppra across 2 strengths as of November 18, 2026 (CMS's NADAC survey). That is the pharmacy's own cost for the medicine, not the price at the counter. No national price was found for levetiracetam injections. The pharmacy prices section of this page lists every strength priced.

Is there a levetiracetam shortage?

No. Levetiracetam is not on the FDA's drug shortage list as of Nov 21, 2026. A single pharmacy can still run short for a while without a national shortage, and your pharmacist can tell you what they are seeing.

Where can I read the levetiracetam prescribing information (package insert)?

The full FDA-approved prescribing information for levetiracetam, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from UCB, Inc.'s, revised Jan 28, 2026, and links to it on DailyMed.

Can you crush levetiracetam?

Some forms of levetiracetam are on our Do Not Crush list of tablets and capsules that should not be crushed or chewed: Elepsia XR (tablet, extended release); Keppra (tablet, film coated); Keppra XR (tablet, extended release); levetiracetam (tablet, extended release). An extended-release form releases the medicine over many hours, and crushing or chewing it can release the whole dose at once. A form that is not on the list may still come with its own instructions, so check the label and ask your pharmacist before you crush, split or open any medicine. Each listed form’s reason and instructions are on our Do Not Crush list.

Is levetiracetam gluten free?

No levetiracetam label we read lists an ingredient made from wheat, barley or rye, the grains that carry gluten, and none names a starch, dextrin or maltodextrin without saying where it comes from. We read the FDA labels of 302 levetiracetam products from 81 companies. A label lists ingredients; it is not a gluten test, so we cannot promise that any product has no gluten. If you have celiac disease, ask the company for a written gluten statement. Our Inactive Ingredient Checker shows each company's levetiracetam by strength and NDC, and whether its label lists a gluten source, lactose, dyes or any other inactive ingredient. See levetiracetam inactive ingredients by company

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Levetiracetam

Skip the scrolling. Ask in your own words and get an answer from Levetiracetam’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Levetiracetam’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Levetiracetam on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, usually within a day.
Detailed Data & References for Levetiracetam Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Levetiracetam Forms and Strengths (How It Comes)

Levetiracetam comes in 4 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Levetiracetam inactive ingredients by manufacturer.

Tablet

By mouth
Brands Keppra (the first brand, 1999) Keppra XR (2008) Spritam (2015) Roweepra
How this form is used
What it may be used for
  • Keppra and Roweepra tablets are used for partial-onset seizures from 1 month of age, plus add-on use for myoclonic and generalized tonic-clonic seizures.
  • Spritam is used for partial-onset seizures in patients 4 and older weighing more than 20 kg, plus add-on use for myoclonic and generalized tonic-clonic seizures.
Important instructions
  • Spritam is meant to disintegrate in the mouth with a sip of liquid and is not swallowed whole.
  • Spritam can also be dispersed in a small amount of liquid and taken right away, or given through a feeding tube.
  • Partial Spritam tablets should not be given.
Available strengths 4 strengths
178 FDA-listed product records ⓘ

Injection

Into a vein
Brands Keppra (the first brand, 1999) Keppra XR (2008)
How this form is used
What it may be used for
  • Keppra injection and Levetiracetam injection are for use only when oral administration is temporarily not feasible.
  • Levetiracetam in Sodium Chloride injection is add-on therapy for adults 16 and older with partial-onset, myoclonic or primary generalized tonic-clonic seizures.
Important instructions
  • Keppra injection is for intravenous use only.
  • Levetiracetam in Sodium Chloride injection is for intravenous infusion over 15 minutes and should not be diluted before use.
Available strengths 8 strengths
Show 2 more strengths Show fewer strengths
65 FDA-listed product records ⓘ

Extended-release tablet

By mouth
Brands Elepsia XR (2018) Keppra (the first brand, 1999) Keppra XR (2008)
How this form is used
What it may be used for
  • Keppra XR and Levetiracetam ER are used for partial-onset seizures in patients 12 and older.
  • Elepsia XR is add-on therapy for partial-onset seizures in patients 12 and older.
Important instructions
  • Keppra XR and Levetiracetam ER are taken once daily and swallowed whole, not chewed, broken or crushed.
  • Elepsia XR is taken once daily and should be taken whole, not split or cut.
  • Elepsia XR is not recommended for moderate or severe kidney impairment.
Available strengths 4 strengths
31 FDA-listed product records ⓘ

Oral solution

By mouth
Brands Keppra (the first brand, 1999) Keppra XR (2008)
How this form is used
What it may be used for
  • Keppra oral solution is used for partial-onset seizures from 1 month of age, with add-on use for myoclonic and generalized tonic-clonic seizures at older ages.
Important instructions
  • Levetiracetam oral solution is used for children weighing 20 kg or less.
  • For children, measure with a calibrated device, not a household teaspoon or tablespoon.
Available strengths 4 strengths
30 FDA-listed product records ⓘ

Levetiracetam on the U.S. Market: Products, Makers and Brands

How Levetiracetam appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

84 companies list 304 Levetiracetam product records with the FDA, mostly as tablet, injection, extended-release tablet; the earliest marketing or approval year on record is 1999. Brand names in the directory today include Keppra, Keppra XR, Spritam and 1 more; the rest are generics.

4
Dose forms ⓘ
84
Labelers (makers, repackagers, distributors)
5
Brand names ⓘ
304
FDA-listed product records ⓘ
1999
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (33) · Unfinished tablet, film coated (11) · Unfinished tablet, film coated, extended release (2) · Unfinished injection, solution, concentrate (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

A-S Medication Solutions5%
Bryant Ranch Prepack5%
Remedyrepack Inc.5%
Solco Healthcare US, LLC4%
Coupler LLC3%
UCB, Inc.3%
Other makers77%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How Widely Levetiracetam Is Used (Medicaid Data)

How many Levetiracetam prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

3,055,070
Medicaid prescriptions filled (Q1–Q4 2025)
$110.8M paid by Medicaid, before rebates

How commonly is Levetiracetam prescribed? Of the 1,682 medications we measure, Levetiracetam ranks #73 by Medicaid prescriptions — more than 96% of them.

Where Levetiracetam ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Levetiracetam product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

The 500 mg oral tablet is the most-dispensed Levetiracetam product — about 30% of these Medicaid prescriptions.

levetiracetam 500 MG Oral Tablet Most dispensed

918,215 Medicaid prescriptions (Q1–Q4 2025) 30% of Levetiracetam prescriptions shown $21.9M paid by Medicaid, before rebates ≈ $24 per prescription, before rebates

27 of 194 listed NDCs had Medicaid claims. RxNorm 311289

levetiracetam 100 MG/ML Oral Solution

808,463 Medicaid prescriptions (Q1–Q4 2025) 26% of Levetiracetam prescriptions shown $29.2M paid by Medicaid, before rebates ≈ $36 per prescription, before rebates

12 of 121 listed NDCs had Medicaid claims. RxNorm 403884

levetiracetam 1000 MG Oral Tablet

571,074 Medicaid prescriptions (Q1–Q4 2025) 19% of Levetiracetam prescriptions shown $24.5M paid by Medicaid, before rebates ≈ $43 per prescription, before rebates

16 of 99 listed NDCs had Medicaid claims. RxNorm 387003

levetiracetam 750 MG Oral Tablet

460,966 Medicaid prescriptions (Q1–Q4 2025) 15% of Levetiracetam prescriptions shown $14.8M paid by Medicaid, before rebates ≈ $32 per prescription, before rebates

23 of 96 listed NDCs had Medicaid claims. RxNorm 311290

levetiracetam 250 MG Oral Tablet

117,815 Medicaid prescriptions (Q1–Q4 2025) 4% of Levetiracetam prescriptions shown $2.8M paid by Medicaid, before rebates ≈ $23 per prescription, before rebates

22 of 113 listed NDCs had Medicaid claims. RxNorm 311288

24 HR levetiracetam 500 MG Extended Release Oral Tablet

89,562 Medicaid prescriptions (Q1–Q4 2025) 3% of Levetiracetam prescriptions shown $9.3M paid by Medicaid, before rebates ≈ $104 per prescription, before rebates

7 of 50 listed NDCs had Medicaid claims. RxNorm 807832

24 HR levetiracetam 750 MG Extended Release Oral Tablet

65,742 Medicaid prescriptions (Q1–Q4 2025) 2% of Levetiracetam prescriptions shown $6.7M paid by Medicaid, before rebates ≈ $102 per prescription, before rebates

8 of 36 listed NDCs had Medicaid claims. RxNorm 846378

5 ML levetiracetam 100 MG/ML Injection

16,644 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $694,270 paid by Medicaid, before rebates ≈ $42 per prescription, before rebates

19 of 50 listed NDCs had Medicaid claims. RxNorm 647121

100 ML levetiracetam 10 MG/ML Injection

4,698 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $155,683 paid by Medicaid, before rebates ≈ $33 per prescription, before rebates

9 of 30 listed NDCs had Medicaid claims. RxNorm 1193358

100 ML levetiracetam 15 MG/ML Injection

833 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $45,357 paid by Medicaid, before rebates ≈ $54 per prescription, before rebates

8 of 28 listed NDCs had Medicaid claims. RxNorm 1193360

100 ML levetiracetam 5 MG/ML Injection

456 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $22,001 paid by Medicaid, before rebates ≈ $48 per prescription, before rebates

7 of 30 listed NDCs had Medicaid claims. RxNorm 1193362

levetiracetam 500 MG Tablet for Oral Suspension

368 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $327,762 paid by Medicaid, before rebates ≈ $891 per prescription, before rebates

1 of 5 listed NDCs had Medicaid claims. RxNorm 1736048

levetiracetam 1000 MG Tablet for Oral Suspension

129 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $114,373 paid by Medicaid, before rebates ≈ $887 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 1736037

levetiracetam 250 MG Tablet for Oral Suspension

61 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $82,423 paid by Medicaid, before rebates ≈ $1,351 per prescription, before rebates

1 of 6 listed NDCs had Medicaid claims. RxNorm 1736045

levetiracetam 750 MG Tablet for Oral Suspension

44 Medicaid prescriptions (Q1–Q4 2025) <1% of Levetiracetam prescriptions shown $36,218 paid by Medicaid, before rebates ≈ $823 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 1736051

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 162 of the 862 listed Levetiracetam NDCs had Medicaid claims.

Compare Levetiracetam Products

A representative set of FDA-listed product records for Levetiracetam — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 200 of 304 products — FDA National Drug Code Directory. See every product, package size and price: browse all 304 Levetiracetam NDCs →

Levetiracetam Side Effects Reported to the FDA (FAERS)

After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Levetiracetam — a signal of what to watch for, not proof the drug caused it.

The effects most often named in FDA reports that mention Levetiracetam are seizure, fatigue, somnolence; about 83% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.

135,112
Reports mentioning it
83%
Reported as serious
12
Distinct effects shown
Most reported effects
Seizure
16,244
Fatigue
5,673
Somnolence
4,253
Epilepsy
4,201
Convulsion
4,083
Fall
3,814
Headache
3,774
Nausea
3,659
Dizziness
3,643
Drug Interaction
3,514
Age groups
Adult · 8,606Elderly · 4,191Neonate · 1,682Child · 1,631Infant · 933Adolescent · 729

Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Levetiracetam in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.

Levetiracetam FDA Approval History

How Levetiracetam went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.

Levetiracetam was first approved by the FDA in 1999 (Brand: KEPPRA · Ucb Inc); the first generic version was approved in 2008. It remains available in U.S. pharmacies today.

1999
Brand approved
Brand: KEPPRA · Ucb Inc
2008
First generic approved
Lower-cost ANDA competition begins
2026
Available today
Active in U.S. pharmacies

Source: Drugs@FDA.

Levetiracetam Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list one Levetiracetam recall since July 2021. It is still ongoing. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.

Ongoing Class I Mar 13, 2025 · Dr. Reddy's Laboratories, Inc.
LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000…
  • Levetiracetam 0.75% in Sodium Chloride Injection 1,000 mg/100 mL (10 mg/mL), 1 x 100mL, Rx Only, Manufactured by: Gland Pharma Limited, Hyderabad, - 500 043 INDIA, Distributor: Dr. Reddy's Laboratori… Lots: Lot: A1540076, Exp 08/31/2026 FDA record D-0365-2025 →

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Levetiracetam in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
5
Strengths
18
Forms in current FDA listings
5 of 5
In current FDA listings No current FDA listing
Ingredient (IN) Levetiracetam RxCUI 114477
  1. Dose form (SCDF) Extended Release Oral Tablet RxCUI 807831
    In current FDA listings
    Its 4 strengths (SCD)
  2. Dose form (SCDF) Injection RxCUI 1790330
    In current FDA listings
    Its 5 strengths (SCD)
  3. Dose form (SCDF) Oral Solution RxCUI 406121
    In current FDA listings
    Its strength (SCD)
  4. Dose form (SCDF) Oral Tablet RxCUI 374617
    In current FDA listings
    Its 4 strengths (SCD)
  5. Dose form (SCDF) Tablet for Oral Suspension RxCUI 1869554
    In current FDA listings
    Its 4 strengths (SCD)

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

What Levetiracetam Costs Pharmacies (NADAC Benchmark)

What pharmacies pay to buy Levetiracetam: the national average from CMS’s weekly NADAC survey, as of Nov 18, 2026. It is the pharmacy’s cost, not your price at the counter.

No national price was found for Levetiracetam injections, so the prices below are for the tablets, extended-release tablets and oral solution only.

How the Pharmacy Price Has Changed

Pick a form, the generic or the brand, and a strength to see how its price has changed since Nov 2023.

Form
Version
Strength

The brands at this strength: Keppra $8.08 and Spritam $10.27 per tablet.

For the generic 250 mg tablet, pharmacies paid an average of $0.057 per tablet as of Nov 18, 2026, down 4.9% from $0.060 a year earlier. The brands at this strength: Keppra $8.08 and Spritam $10.27 per tablet.

What pharmacies pay now
$0.057
per tablet, as of Nov 18, 2026
Last 4 weeks
Up 0.4%
from $0.057 on Oct 21, 2026
Last 12 months
Down 4.9%
from $0.060 on Nov 19, 2025
Lowest and highest since Nov 2023
$0.045 to $0.074
per tablet

Each step is one weekly survey. Arrow keys on the chart move week by week.
See the numbers, month by month
Generic 250 mg tablet: the average pharmacy price per tablet, the last survey of each month
MonthPharmacy price
Nov 2026$0.057
Oct 2026$0.057
Sep 2026$0.056
Aug 2026$0.058
Jul 2026$0.059
Jun 2026$0.060
May 2026$0.059
Apr 2026$0.058
Mar 2026$0.056
Feb 2026$0.057
Jan 2026$0.059
Dec 2025$0.061
Nov 2025$0.060
Oct 2025$0.059
Sep 2025$0.060
Aug 2025$0.063
Jul 2025$0.063
Jun 2025$0.064
May 2025$0.061
Apr 2025$0.060
Mar 2025$0.061
Feb 2025$0.057
Jan 2025$0.053
Dec 2024$0.051
Nov 2024$0.045
Oct 2024$0.061
Sep 2024$0.063
Aug 2024$0.065
Jul 2024$0.049
Jun 2024$0.067
May 2024$0.051
Apr 2024$0.055
Mar 2024$0.063
Feb 2024$0.064
Jan 2024$0.065
Dec 2023$0.070
Nov 2023$0.074
See all 15 prices in a table
FormStrengthVersion What pharmacies pay
Tablet · Oral 250 mg Generic $0.057 per tablet NDC details & price history
Tablet · Oral 250 mg Keppra (brand) $8.08 per tablet NDC details & price history
Tablet · Oral 250 mg Spritam (brand) $10.27 per tablet NDC details & price history
Tablet · Oral 500 mg Generic $0.073 per tablet NDC details & price history
Tablet · Oral 500 mg Keppra (brand) $9.91 per tablet NDC details & price history
Tablet · Oral 500 mg Spritam (brand) $10.24 per tablet NDC details & price history
Tablet · Oral 750 mg Generic $0.116 per tablet NDC details & price history
Tablet · Oral 1000 mg Generic $0.167 per tablet NDC details & price history
Tablet · Oral 1000 mg Spritam (brand) $10.20 per tablet NDC details & price history
Extended-release tablet · Oral 500 mg Generic $0.182 per tablet NDC details & price history
Extended-release tablet · Oral 500 mg Keppra (brand) $9.00 per tablet NDC details & price history
Extended-release tablet · Oral 750 mg Generic $0.250 per tablet NDC details & price history
Extended-release tablet · Oral 750 mg Keppra (brand) $13.48 per tablet NDC details & price history
Oral solution · Oral 100 mg/mL Generic $0.030 per mL NDC details & price history
Oral solution · Oral 100 mg/mL Keppra (brand) $1.92 per mL NDC details & price history
Why it helps: it shows whether the drug itself is cheap or costly, and whether a cash price you are quoted is in a reasonable range. What you pay also depends on your insurance and pharmacy.

Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.

Levetiracetam Brand Names

Levetiracetam has 5 brand names on record: Elepsia XR, Keppra, Keppra XR, Spritam and others. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Elepsia XR 2018 Keppra the first brand, 1999 Keppra XR 2008 Spritam 2015 Roweepra

Who Makes Levetiracetam: Manufacturers and Labelers

84 companies list Levetiracetam products with the FDA. By number of product records, the largest are A-S Medication Solutions, Bryant Ranch Prepack, Remedyrepack Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

A-S Medication Solutions 14 Bryant Ranch Prepack 14 Remedyrepack Inc. 14 Solco Healthcare US, LLC 11 Coupler LLC 8 UCB, Inc. 8 BluePoint Laboratories 6 Cardinal Health 107, LLC 6 Dr.Reddy's Laboratories Inc 6 Lupin Pharmaceuticals, Inc. 6 Novadoz Pharmaceuticals LLC 6 ScieGen Pharmaceuticals, Inc. 6 Torrent Pharmaceuticals Limited 6 American Health Packaging 5 Amneal Pharmaceuticals LLC 5 Aurobindo Pharma Limited 5 Camber Pharmaceuticals, Inc. 5 Direct_Rx 5 Hikma Pharmaceuticals USA Inc. 5 Major Pharmaceuticals 5 NorthStar RxLLC 5 Asclemed Usa Inc. 4 Aprecia Pharmaceuticals, LLC 4 Ascend Laboratories, LLC 4

…and 60 more on the FDA NDC directory.

Sources for This Levetiracetam Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Jan 28, 2026, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Levetiracetam.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 145 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
145
Finished products in the current FDA directory
304
Companies listing them (makers, repackagers, distributors)
84
FDA labeler codes behind them ⓘ
90
Linked representative label ⓘ
UCB, Inc.
Linked label effective
Jan 28, 2026
Composite sections available
23
Linked SPL Set ID
3ca9df05-a506-4ec8-a4fe-320f1219ab21
Linked SPL Document ID
4974b225-87ca-610e-e063-6294a90ad20a
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. UCB, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →